Phathom Pharmaceuticals Inc
(NAS:PHAT)
$
13.84
1.03 (8.04%)
Market Cap: 945.13 Mil
Enterprise Value: 844.17 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 30/100 - Q4 2023 Phathom Pharmaceuticals Inc Earnings Call TranscriptMar 07, 2024$9.09 (-6.58%)Earnings
- Phathom Pharmaceuticals Inc to Discuss The FDA Approval TranscriptNov 02, 2023
- Phathom Pharmaceuticals Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Phathom Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) TranscriptApr 18, 2023
- Phathom Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) TranscriptApr 12, 2022
- Phathom Pharmaceuticals Inc Conference call on the PHALCON-EE Trial Results TranscriptOct 18, 2021
- Phathom Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2021
- Phathom Pharmaceuticals Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 01, 2021
- Phathom Pharmaceuticals Inc Annual Shareholders Meeting TranscriptMay 21, 2021
- Phathom Pharmaceuticals Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 13, 2021
- Phathom Pharmaceuticals Inc Phase 3 PHALCON-HP Results Corporate Call TranscriptApr 29, 2021
- Phathom Pharmaceuticals Inc Corporate Analyst Meeting TranscriptDec 14, 2020
- Phathom Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 15, 2020
- Phathom Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Phathom Pharmaceuticals Inc Annual Shareholders Meeting TranscriptMay 21, 2020
Phathom Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 18, 2023 / 12:45PM GMT
Release Date Price:
$9.94
(-4.61%)
Joey Stringer
Needham & Company - Analyst
Good morning, everyone. Thank you for joining the 22nd Annual Needham Healthcare Conference. My name is Joey Stringer, and I'm one of the biotech analysts at Needham & Company. It's my pleasure to introduce our next presenting company, that's Phathom Pharmaceuticals. Joining us today from the company is President and CEO, Terrie Curran; CFO, Molly Henderson; Chief Operating Officer, Azmi Nabulsi; Chief Commercial Officer, Martin Gilligan; and also, Chief Development Officer, Tom Harris. I think I got everyone.
(Conference Instructions) So, with that, that was with the Phanthom team. Thanks so much for joining us today.
Terrie Curran
Phathom Pharmaceuticals, Inc. - President & CEO
Thanks, Joey, and thanks for the invitation to be here. It's a real pleasure.
Joey Stringer
Needham & Company - Analyst
Of course.
Terrie Curran
Phathom Pharmaceuticals, Inc. - President & CEO
So, I'll pick it up, and I
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)